RankAlpha logo
Back to Rankings

IKT

Inhibikase TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
IKT vs peer average
37/100
IKT vs. peer average (D vs. C)
Grade spread
A 1 · B 3 · C 2 · D 1 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked

Peer overview

GOSS is the first available peer comparator.

Gossamer Bio is the closest late-stage development comparator: its official materials describe seralutinib in PAH and note Phase 3 PROSERA enrollment completion, which makes it relevant for benchmarking pivotal-study execution, readout sensitivity, and PAH-specialist investor expectations.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerGOSSGossamer Bio
IKT
Inhibikase Therapeutics
GOSS
Gossamer Bio
Grade
D
F
Momentum
84
2
Value
41
41
Sentiment
32
0
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare all

Grade position vs GOSS

IKT / GOSS
Grade Position
Below peers
IKT vs. peer average (D vs. C)
37/100
Momentum
84
IKT
Value
41
IKT
Sentiment
32
IKT

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs IKT
1
GOSS
GOSS
A
100/100
-3
2
LQDA
LQDA
B
80/100
-2
3
KROS
KROS
B
80/100
-2
4
LYEL
Lyell Immunopharma Inc Common
F
20/100
+1
5
IMRX
Immuneering Corp Class A Common
C
60/100
-1
GOSS is the first peer returned for this comparison set.